Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ARTICULATE PRO study logo

ARTICULATE PRO is a two-year project, funded by the Accelerative Access Collaborative and NHSx through a Phase 4 AI in Health and Care Award. The project officially began on 1 September 2021.  

Our remit is to investigate the deployment of AI (computer assisted technology) in the prostate cancer pathway by using Paige Prostate to assist pathologists when reading prostate biopsies.

We have a multi-disciplinary, expert team, led by Associate Professor Clare Verrill of the Nuffield Department of Surgical Sciences, University of Oxford, in conjunction with our industry partner, Paige AI. (See "The TEAM" for more information).

York Heath Economics Consortium has been appointed as our TSET (Technology Specialist Evaluation Team) and they will undertake a programme of work looking at health economics amongst other things.

We are delighted to be joined by three patient representatives on the study too, who bring a very unique view point to the project and a wealth of experience as patients.

We are also grateful to Prostate Cancer UK for their support of the study. The excerpt below is from a letter from PCUK supporting our funding application..........

Your new study builds on this incredible innovation to deliver the next important step in augmenting pathologists’ expertise and capacity. It offers patients a future with the potential for fewer missed cancers, with AI pointing the pathologists to the relevant areas. There is also the potential for better patient outcomes though improved detection and reproducibility. At the same time, AI can create efficiencies among a workforce facing increased demand for its services and experiencing more complex reporting requirements. It can also enable novel insights into disease biology, which is critical to our understanding of the natural history of prostate cancer, and which cannot be derived by human interpretations of patterns and morphology alone. We believe this will make a real difference for men facing a diagnosis of prostate cancer and we fully support it.
- Prostate Cancer UK